Literature DB >> 12616204

Olfactory neuroblastoma: past, present, and future?

Valerie J Lund1, David Howard, William Wei, Margaret Spittle.   

Abstract

OBJECTIVE: To consider the long-term survival and outcomes in patients with olfactory neuroblastoma undergoing craniofacial resection. STUDY
DESIGN: A single-center prospective cohort study.
METHODS: All patients with olfactory neuroblastoma treated in a 23-year period with craniofacial resection (with or without radiotherapy) were analyzed; a multivariate analysis was included.
RESULTS: Forty-two patients aged 12 to 70 years were assessed, 83% of whom had received no preceding treatment. Craniofacial resection was used in all cases, combined with radiotherapy in 24 patients (57%). Duration of follow-up ranged from 2 to 206 months (mean follow-up period, 57 mo). The disease-free actuarial survival and overall survival were 77% and 61% at 5 years and 53% and 42% at 10 years, respectively. A Cox regression analysis identified intracranial extension and orbital involvement as independent factors affecting outcome.
CONCLUSION: Craniofacial resection combined with radiotherapy offers the gold standard of care against which other approaches such as endoscopic resection must be judged.

Entities:  

Mesh:

Year:  2003        PMID: 12616204     DOI: 10.1097/00005537-200303000-00020

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  56 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

2.  Transcranial resection of olfactory neuroblastoma.

Authors:  Chih-Chun Wang; Yao-Liang Chen; Yung-Shin Hsu; Shih-Ming Jung; Sheng-Po Hao
Journal:  Skull Base       Date:  2005-08

Review 3.  A primary sellar esthesioneuroblastomas with unusual presentations: a case report and reviews of literatures.

Authors:  Jiann-Her Lin; Dong-Han Tsai; Yung-Hsiao Chiang
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

4.  Esthesioneuroblastoma with large intracranial extension treated with Induction chemotherapy, de-bulking surgery and image guided intensity modulated radiotherapy.

Authors:  Prashanth Giridhar; Supriya Mallick; M A Laviraj; Suman Bhasker
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-04       Impact factor: 2.503

Review 5.  Long-term carcinologic results of advanced esthesioneuroblastoma: a systematic review.

Authors:  Guillaume De Bonnecaze; B Lepage; J Rimmer; A Al Hawat; B Vairel; E Serrano; B Chaput; S Vergez
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-17       Impact factor: 2.503

6.  Positron emission computed tomography and magnetic resonance imaging features of sinonasal small round blue cell tumors.

Authors:  Kerem Ozturk; Mehmet Gencturk; Emiro Caicedo-Granados; Faqian Li; Zuzan Cayci
Journal:  Neuroradiol J       Date:  2019-08-28

Review 7.  Olfactory neuroblastoma.

Authors:  Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2009-07-16

8.  Orbital preservation in patients with esthesioneuroblastoma.

Authors:  Marc W Herr; Stacey T Gray; Audrey B Erman; William T Curry; Daniel G Deschler; Derrick T Lin
Journal:  J Neurol Surg B Skull Base       Date:  2013-03-13

9.  Intranasal Esthesioneuroblastoma: CT Patterns Aid in Preventing Routine Nasal Polypectomy.

Authors:  M E Peckham; R H Wiggins; R R Orlandi; Y Anzai; W Finke; H R Harnsberger
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

10.  Use of 18F-fluorodeoxyglucose positron emission tomography in patients with rare head and neck cancers.

Authors:  Jong-Lyel Roh; Byoung Jae Moon; Jae Seung Kim; Jeong Hyun Lee; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Bong-Jae Lee; Sang Yoon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-06-20       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.